Conversely, Cohen and colleagues showed that CIMP+ status based on the same panel of methylation markers did not affect overall survival in CRC patients, but it was associated with right-side tumor location and BRAF mutations [51]. This evidence concerns the gene BRAF and colorectal carcinoma.